Testing of the Akt/PKB inhibitor MK-2206 by the pediatric preclinical testing program

Background MK-2206 is a small molecule allosteric inhibitor of Akt/PKB that is undergoing clinical trials for treatment of cancer. Procedures MK-2206 was tested against the PPTP in vitro panel using a 96-hour exposure (1.0?nM10?mu M), and in vivo using thrice weekly dosing for a planned 4 weeks at its maximum tolerated dose (MTD) of 180?mg/kg. Results In vitro, the median relative IC50 value for MK-2206 was 2.2?mu M. Four cell lines with IC50 values?